# Contents

## Part I Introduction Into Kala-Azar

1. **Pathology and Mechanism of Disease in Kala-Azar**
   Shyamal Paul and Monira Pervin
   
   3

2. **Containing Post Kala-Azar Dermal Leishmaniasis (PKDL): Pre-requisite for Sustainable Elimination of Visceral Leishmaniasis (VL) from South Asia**
   Poonam Salotra, Himanshu Kaushal and V. Ramesh
   
   7

3. **Characteristics of Patients Visiting Suruya Kanta Kala-Azar Research Center in Mymensingh, Bangladesh; Data from a Patient Registry System**
   Masao Iwagami, Bumpei Tojo and Eisei Noiri
   
   23

## Part II Therapeutic Strategy to Deal with Emergence of Drug Resistance

4. **Epidemiology of Drug-Resistant Kala-Azar in India and Neighboring Countries**
   T.K. Jha
   
   33

5. **A Therapeutic Strategy for Treating Visceral Leishmaniasis in Regions with Drug Resistance**
   Shyam Sundar and Dipti Agarwal
   
   53

6. **Treatment of Post-kala-azar Dermal Leishmaniasis**
   V. Ramesh and Prashant Verma
   
   67

7. **Combination Therapy for Leishmaniases**
   Farrokh Modabber
   
   79

8. **Vaccine Development for Leishmaniasis**
   Yasuyuki Goto
   
   89
9 Siccanin Is a Novel Selective Inhibitor of Trypanosomatid Complex II (Succinate-Ubiquinone Reductase) and a Potent Broad-Spectrum Anti-trypanosomatid Drug Candidate ........... 101
Nozomu Nihashi, Daniel Ken Inaoka, Chiaki Tsuge, Emmanuel Oluwadare Balogun, Yasutaka Osada, Yasuyuki Goto, Yoshitsugu Matsumoto, Takeshi Nara, Tatsushi Mogi, Shigeharu Harada and Kita Kiyoshi

Part III Diagnostic Strategy Enhancing Kala-Azar Elimination Program

10 Challenges in the Diagnosis of Visceral Leishmaniasis on the Indian Subcontinent .................................................. 125
Suman Rijal, François Chappuis, Jorge Alvar and Marleen Boelaert

11 Changes of Leishmania Antigens in Kala-Azar Patients’ Urine After Treatment ........................................... 135
Sharmina Deloer, Sohel Mohammad Samad, Hidekazu Takagi, Chatanun Eamudomkarn, Kazi M. Jamil, Eisei Noiri and Makoto Itoh

12 Potentiality of Urinary L-FABP Tests to Kala-Azar Disease Management ......................................................... 141
Eisei Noiri, Yoshifumi Hamasaki, Bumpei Tojo, Kazi M. Jamil, Kent Doi and Takeshi Sugaya

13 Antibody Capture Direct Agglutination Test (abcDAT) for Diagnosis of Visceral Leishmaniasis with Urine .......... 161
Fumiaki Nagaoka, Hidekazu Takagi, Eisei Noiri and Makoto Itoh

14 Loop-Mediated Isothermal Amplification (LAMP): Molecular Diagnosis for the Field Survey of Visceral Leishmaniasis ........ 167
Hidekazu Takagi, Makoto Itoh and Eisei Noiri

15 Applicability of Multiplex Real-Time PCR to Visceral Leishmaniasis ................................................................. 173
Yoshifumi Hamasaki, Hirofumi Aruga, Chizu Sanjoba, Hidekazu Takagi, Shyamal Paul, Yoshitsugu Matsumoto and Eisei Noiri

Part IV Pathogenesis of Kala-Azar and PKDL

16 Immunoglobulins in the Pathophysiology of Visceral Leishmaniasis .............................................................. 187
Satoko Omachi, Yoshitsugu Matsumoto and Yasuyuki Goto
Part V Knowledge and Practice for Vector Control in Kala-Azar

17 Geographical Distribution and Ecological Aspect of Sand Fly Species in Bangladesh .......................... Yusuf Özbél, Chizu Sanjoba and Yoshitsugu Matsumoto

18 The Efficacy of Long Lasting Insecticidal Nets for Leishmaniasis in Asia .................................. Chizu Sanjoba, Yusuf Özbél and Yoshitsugu Matsumoto

Part VI New Challenges in Kala-Azar Elimination Programme


20 Drug Safety Monitoring for Liposomal Amphotericin B .......... Eisei Noiri and Kosuke Minami

21 High Resolution Mapping of Kala-Azar Hot Spots Using GPS Logger and Urinary Antibody Measurements .......... Bumpei Tojo, Makoto Itoh, Mohammad Sohel Samad, Emi Ogasawara, Dinesh Mondal, Rashidul Haque and Eisei Noiri

22 Geography and Reality of Kala-Azar Endemic in Bangladesh, Analysis Using GIS and Urine-Based Mass Screening .......... Bumpei Tojo, Makoto Itoh, Shyamal Kumar Paul, Mohammad Sohel Samad, Emi Ogasawara, Fumiaki Nagaoka, Dinesh Mondal, Rashidul Haque and Eisei Noiri

23 Animal Models of Visceral Leishmaniasis and Applicability to Disease Control ................................. Yasutaka Osada, Satoko Omachi, Chizu Sanjoba and Yoshitsugu Matsumoto

24 Pharmacovigilance on Therapeutic Protocols for Visceral Leishmaniasis ........................................ Eisei Noiri, Bumpei Tojo, Yoshifumi Hamasaki, Masao Iwagami, Takeshi Sugaya, Michiyo Harada, Progga Nath, Ariful Basher, Dinesh Mondal, Rashidul Haque, Md Fashiur Rahman and Shyamal Paul
Erratum to: Pharmacovigilance on Therapeutic Protocols for Visceral Leishmaniasis
Eisei Noiri, Bumpei Tojo, Yoshifumi Hamasaki, Masao Iwagami, Takeshi Sugaya, Michiy...
Kala Azar in South Asia
Current Status and Sustainable Challenges
Noiri, E.; Jha, T.K. (Eds.)
2016, XX, 309 p. 85 illus., 54 illus. in color., Hardcover
ISBN: 978-3-319-43611-1